Genetic Evidence Identified for Role of IDO in Tumorigenesis

This article originally appeared here.
Share this content:
Genetic Evidence Identified for Role of IDO in Tumorigenesis
Genetic Evidence Identified for Role of IDO in Tumorigenesis

(HealthDay News) – Mice deficient in indoleamine 2,3-dioxygenase (IDO) have reduced tumor burden and improved survival, with greatly attenuated interleukin-6 (IL-6) and impaired protumorigenic myeloid-derived suppressor cells (MDSC) seen in conjunction with the loss of IDO, according to a study published online July 19 in Cancer Discovery.

Courtney Smith, PhD, from the Lankenau Institute for Medical Research in Wynnewood, PA, and colleagues generated mice deficient in IDO to examine the role of the enzyme in mouse models of lung cancer and breast cancer-derived lung metastasis.

The researchers found that IDO-deficient mice had smaller lung cancers and improved survival. Micro-computed tomography imaging showed reduced density of the underlying pulmonary blood vessels. Both tumor models also had greatly reduced production of IL-6, which resulted in impairment of protumorigenic MDSC.

"This study provides preclinical, genetic proof-of-concept that the immunoregulatory enzyme IDO contributes to autochthonous carcinoma progression and to the creation of a metastatic niche," Smith and colleagues conclude. "IDO deficiency in vivo negatively impacted both vascularization and IL-6-dependent, MDSC-driven immune escape, establishing IDO as an overarching factor directing the establishment of a protumorigenic environment."

One author is an employee of NewLink Genetics Corporation; several authors disclosed financial and consulting ties to NewLink.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs